The Burden of Multiple Myeloma

Thanks for joining the march!

Latest newsletter

Read our latest update: the April 2019 newsletter

Latest News

Dual CAR T-cell combination a ‘promising treatment option’ for multiple myeloma

A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with relapsed...
Continue Reading

Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data

Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with multiple myeloma, but...
Continue Reading

Government urged to expand Pharmac’s drug budget after barrage of emotional pleas from sufferers

This story was originally published on Stuff “Why does New Zealand need to reinvent the wheel?” Posed by National MP...
Continue Reading

Health Select Committee hears pleas from survivors and sufferers

This story was originally published on RNZ Politicians heard emotional pleas today from cancer survivors, people with disabilities and health...
Continue Reading

Blood cancer patient advocacy group presents to Health Select Committee to fund life-extending treatments

Dr Ken Romeril, chief executive, Myeloma New Zealand, is appearing today before the Health Select Committee in support of their...
Continue Reading

Dr. Nadeem on Individualizing Therapy in Multiple Myeloma

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing...
Continue Reading


Every quarter we’ll post news and information in our myeloma newsletter. If you would like to join the community of patients and caregivers receiving this subscribe below.